Verge Genomics & Alexion collaborate for AI-Enabled Drug Discovery

Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M The collaboration is the second with a leading global pharmaceutical company and shows the unique scalability of the CONVERGE™ platform for technology-enabled drug discovery Verge Genomics, a clinical-stage biotechnology company transforming...

The post Verge Genomics & Alexion collaborate for AI-Enabled Drug Discovery first appeared on AI-TechPark.

ai biotechnology clinical collaboration converge discovery drug discovery future genomics global milestones near payments pharmaceutical platform scalability shows stage technology